Skip to main content
Psychiatry News

Saladax Biomedical Announces Health Canada Approval of Five MyCare™ Psychiatry Laboratory Diagnostic Assay

By February 17, 2021November 6th, 2021No Comments

BETHLEHEM, Pa.–(BUSINESS WIRE)–Saladax Biomedical, Inc. (Saladax) is pleased to announce the approval of five MyCare™ Psychiatry Laboratory Assays by Health Canada for use in measuring drug levels in patients prescribed any of the six most common antipsychotic drugs.

The MyCare Psychiatry Laboratory Assays are essential diagnostic tools used by psychiatrists to monitor the patient’s blood concentration level of these prescribed drugs. These assays run on chemistry analyzers already present in most clinical laboratories, and the test results are available within hours instead of days.

The approved MyCare Psychiatry Laboratory Assays provide blood drug concentration levels for clozapine, risperidone, paliperidone, aripiprazole, olanzapine, and quetiapine.

“The ability of our assays to provide results within hours means that clinicians for the first time will now have a convenient diagnostic tool to assist in the management and optimization of their patient’s therapy,” stated Sal Salamone, CEO and Founder of Saladax.

These assays are available in Canada through HLS Therapeutics Inc., the exclusive Canadian distributor of Saladax’s MyCare™ Psychiatry Laboratory Assays.

Headquartered in Bethlehem, PA, Saladax Biomedical, Inc. is a privately held company that develops, manufactures, and markets assays that provide rapid therapeutic drug levels for essential and life-saving medicines prescribed by psychiatrists and oncologists. Since 2007, Saladax’s proprietary technology has been used in clinical laboratories or point-of-care settings to assist clinicians monitor and optimize patient care. Additionally, the company collaborates with leading pharmaceutical companies to develop tests for clinical trials and companion diagnostics. For more information, visit

Formed in 2015, HLS is a specialty pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial-stage promoted and established branded pharmaceutical products in the North American markets. HLS’s focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS’s management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information, please visit:

For more information, visit or


Saladax Biomedical, Inc.
Salvatore Salamone, Ph.D., 610-419-6731

This will close in 20 seconds

This will close in 20 seconds